FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, immunology and virology. Described is an expression vector for producing an immunobiological agent for inducing an immune response against the SARS-CoV-2 virus, based on human adenovirus serotype 26 and having a sequence SEQ ID NO: 1, or SEQ ID NO: 2, or SEQ ID NO: 3. Also disclosed is an expression vector based on human adenovirus serotype 5 and having the sequence SEQ ID NO: 4, or SEQ ID NO: 5, or SEQ ID NO: 6, and an expression vector based on human adenovirus serotype 5 and having the sequence SEQ ID NO: 7, or SEQ ID NO: 8, or SEQ ID NO: 9. Also disclosed is an immunobiological agent containing the declared expression vectors, use of this agent for inducing an immune response against SARS-CoV-2 virus. Also described is a method of inducing an immune response involving sequential or simultaneous administration of the versions of the immunobiological agent in an effective amount.
EFFECT: group of inventions provides creating a safe immunobiological agent inducing a specific immune response against the SARS-CoV-2 coronavirus.
7 cl, 4 dwg, 6 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) | 2021 |
|
RU2743963C1 |
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LYOPHILIZED FORM (VERSIONS) | 2021 |
|
RU2743962C1 |
| DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN | 2021 |
|
RU2761904C1 |
| USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION (VERSIONS) | 2021 |
|
RU2744444C1 |
| USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION IN PEOPLE OVER 60 AND/OR WITH CHRONIC DISEASES (VERSIONS) | 2021 |
|
RU2744442C1 |
| Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCING IMMUNE RESPONSE AGAINST LASSA VIRUS AND METHOD FOR USING IT | 2024 |
|
RU2823965C1 |
| PHARMACEUTICAL AGENT AND METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) | 2020 |
|
RU2731342C1 |
| EXPRESSION VECTOR FOR CREATING IMMUNOBIOLOGICAL AGENT FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) | 2020 |
|
RU2731356C1 |
